| Literature DB >> 32638111 |
Ulf R Jensen-Kondering1, Caroline Weiler2, Patrick Langguth3, Naomi Larsen3, Charlotte Flüh4, Gregor Kuhlenbäumer2, Olav Jansen3, Nils G Margraf2.
Abstract
BACKGROUND: The key imaging features of cerebral amyloid angiopathy (CAA) are lobar, cortical, or cortico-subcortical microbleeds, macrohaemorrhages and cortical superficial siderosis (cSS). In contrast, hypertensive angiopathy is characterized by (micro) haemorrhages in the basal ganglia, thalami, periventricular white matter or the brain stem. Another distinct form of haemorrhagic microangiopathy is mixed cerebral microbleeds (mixed CMB) with features of both CAA and hypertensive angiopathy. The distinction between the two entities (CAA and mixed CMB) is clinically relevant because the risk of haemorrhage and stroke should be well balanced if oral anticoagulation is indicated in CAA patients. We aimed to comprehensively compare these two entities.Entities:
Keywords: Cerebral amyloid angiopathy; Hypertensive angiopathy; Microbleed; Modified Boston criteria; SWI
Mesh:
Year: 2020 PMID: 32638111 PMCID: PMC7674181 DOI: 10.1007/s00415-020-10038-8
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Fig. 1a, b Susceptibility-based MRI in a patient with probable CAA. Cerebral microbleeds in lobar location (circles) and cortical superficial siderosis (arrows). c, d Susceptibility-based MRI in a patient with mixed CMB. Cerebral microbleeds in lobar location (circles) and additional deep microbleeds (boxes) in the brain stem (c) and thalami (d)
Clinical and radiological characteristics of patients with CAA and mixed CMB
| Characteristics | CAA ( | Mixed CMB ( | |
|---|---|---|---|
| Age, mean (SD) years | 78 (8) | 74 (9) | |
| Female sex, | 23 (44) | 19 (43) | 0.918b |
| Reason for MRI | |||
| Suspected Stroke, | 33 (62)e | 24 (53)f | 0.358b |
| Seizure, | 5 (9)e | 4 (9)f | 1c |
| Dementia, | 2 (4)e | 6 (13)f | 0.247c |
| Other, | 13 (25)e | 12 (26)f | 0.907b |
| Clinical event to MRI, median, (range) days | 3 (0–15)n=43 | 3 (0–17) | 0.315d |
| Acute ischemic stroke, | 22 (42) | 18 (41) | 0.889b |
| Previous ischemic stroke, | 22 (42) | 22 (49) | 0.516b |
| Anticoagulation or platelet inhibition, | 30 (61) | 30 (66) | 0.483b |
| Diabetes mellitus, | 12 (24) | 10 (23) | 0.926b |
| Insulin dependency, | 4 (33) | 5 (50) | 0.665c |
| Arterial hypertension, | 38 (75) | 39 (89) | |
| Number of antihypertensive drugs, median (range) | 2 (0–6) | 2 (0–6) | 0.736d |
| Hypercholesterinemia, | 18 (38) | 19 (43) | 0.578b |
| LDL, mean (SD) mg/dl | 2.86 (0.875) | 3.00 (1.25) | 0.587a |
| Statin medication, | 21 (44) | 13 (30) | 0.158b |
| Creatinine, mean (SD) mg/dl | 91 (27.73)n=45 | 89.51 (27.76)n=41 | 0.805a |
| Smoking, | 13 (34)n=38 | 7 (22)n=32 | 0.255b |
| Dementia, | 13 (25) | 14 (32) | 0.459b |
| WML pattern subcortical, | 39 (75) | 30 (68) | 0.459b |
| WML pattern peri BG, | 9 (17) | 10 (23) | 0.386b |
| WML pattern posterior, | 48 (92) | 37 (84) | 0.223b |
| WML pattern frontal, | 36 (69) | 35 (80) | 0.226b |
| WMH volume, mean (SD) ml | 14 (11)n=51 | 18 (19)n=43 | 0.138a |
| BG EPVS high degree (score > 20), | 36 (69) | 30 (68) | 0.912b |
| CSO EPVS high degree (score > 20), | 29 (56) | 22 (50) | 0.572b |
| Lacunes ≥ 1, | 26 (50) | 32 (73) | |
| Rate of lobar lacunes (%) | 73 | 69 | 0.81b |
| Rate of deep lacunes (%) | 23 | 51 | |
| High CMB count (> 10), | 25 (48) | 30 (67) | |
| Presence of cSS, | 10 (19) | 2 (4) |
SD standard deviation, MRI magnetic resonance imaging, LDL low density lipoprotein, WML white matter lesions, BG basal ganglia, EPVS enlarged perivascular spaces, CSO centrum semiovale, CMB cerebral microbleeds, cSS cortical superficial siderosis
at test
bChi-square test
cFisher’s exact test
dMann–Whitney U test
One (e) and two (f) patients with more than one reason for MRI
Bold values indicate p < 0.1
Fig. 2Comprehensive depiction of the location, extent and cumulative quantity of cortical superficial siderosis in CAA patients (n = 10, 19%) and mixed CMB patients (n = 2, 4%). No cSS was detected below the level of the basal ganglia